Table 7.
Studies comparing different reported outcomes between intravitreal anti-VEGF and LPC/PRP as treatment modalities for TR-ROP that are useful for clinical ophthalmologists
| Authors/first author | Study type | Year | Participants | Treatment modalities being compared | Outcomes | Risk of bias assessment with RoB 2 tool8 or with ROBINS-I tool9 |
|---|---|---|---|---|---|---|
| Cilsal and Sukgen [58] | Observational study | 2020 | 51 infants with TR-ROP |
IVA (1 mg/0.025 ml), Diode LPC, control group |
IVA group had: Higher tricuspid E-wave values compared to the diode LPC group (P = 0.020) Control group had: Lower tricuspid E-wave values compared to the two treatment groups (P = 0.040) |
Serious overall risk of bias due to baseline confounding |
| Barry et al. [59] | Observational study | 2019 | 138 infants with TR-ROP |
IVB (dose unspecified), PRP (type unspecified) |
IVB group had: More odds of returning to their respiratory baseline by 48 h (OR: 0.18; 95% CI: 0.05–0.67) |
Serious overall risk of bias due to missing information in two domains of risk of bias assessment |
| Chen et al. [54] | Observational study | 2018 | 49 eyes of 25 patients (8 patients with Zone I plus with stage 1, 2, 3; no plus stage 3, 2 patients with Zone II no plus with stage 1, 2, 3, 14 patients with Zone II plus with stage 1, 2, 3, and one patient with Zone III plus) with treatment-warranted ROP |
IVB (0.625 mg/0.025 ml), Diode LPC |
IVB group had: Lower number of diagnoses at time of discharge (P = 0.004) No differences between groups in: Mean of hospitalization days (P = 0.110 for total length of stay and P = 0.680 for length of stay after primary treatment) Days for oxygen requirement (P = 0.910 for duration of hospitalization, P = 0.790 after initial treatment) |
Serious overall risk of bias due to bias in measurement of the outcomes |
| Kong et al. [57] | Randomized clinical trial | 2015 | 24 infants with type 1 ROP |
IVB (0.625 mg per eye per dose), IVB (0.25 mg per eye per dose), Diode LPC |
Both IVB groups had: More decreased serum-free VEGF levels than the LPC group (P < 0.001) More decreased serum IGF-1 levels than the LPC group (P < 0.050) |
High overall risk of bias (“High” in RoB 2 Tool) |
anti-VEGF anti-vascular endothelial growth factor, LPC laser photocoagulation, PRP panretinal photocoagulation, TR-ROP treatment-requiring retinopathy of prematurity, RoB 2 version 2 of the Cochrane risk-of-bias tool for randomized trials, ROBINS-I risk of bias in non-randomized studies of interventions, IVB intravitreal bevacizumab, ROP retinopathy of prematurity, IGF-1 insulin-like growth factor 1, IVA intravitreal aflibercept, OR odds ratio, CI confidence interval